RealFeedApp Personalized cancer vaccine
A clinical trial showed that combining a personalized cancer vaccine with immunotherapy reduced the risk of death or melanoma recurrence by 42%, while lowering melanoma spread risk by 38% over two years. Manufacturers MSD and Moderna are already testing this approach against other tumors.
- Field
- cancer research
- What they did
- Researchers tested a personalized cancer vaccine combined with an existing immunotherapy drug and found it reduced the risk of death or melanoma recurrence by 42%.
- Why it matters
- This combination also lowered the risk of melanoma spreading by 38% over two years, potentially helping more patients live longer.
#personalized vaccine#melanoma#immunotherapy#clinical trial#msd#moderna
